Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

被引：2

作者：

Vicente, Alana ^{[1
]}

Gutierrez-Rodrigues, Fernanda ^{[1
]}

Giudice, Valentina ^{[1
]}

Wu, Zhijie ^{[1
]}

Kajigaya, Sachiko ^{[1
]}

Ibanez, Maria del Pilar Fernandez ^{[1
]}

Albitar, Maher ^{[2
]}

Weinstein, Barbara ^{[1
]}

Calvo, Katherine R. ^{[1
]}

Townsley, Danielle M. ^{[1
]}

Scheinberg, Phillip ^{[3
]}

Dunbar, Cynthia E. ^{[1
]}

Young, Neal S. ^{[1
]}

Winkler, Thomas ^{[1
]}

机构：

[1] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA

[2] NeoGenomics, Valley Ctr, CA USA

[3] Hosp A Beneficencia Portuguesa, Div Hematol, Sao Paulo, Brazil

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-119780

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

229

引用

页数：3

共 50 条

[21] Evidence of polyclonal hematopoiesis in a large proportion of patients with low-risk myelodysplastic syndrome.
Malcovati, L
Della Porta, MG
Galli, A
Boggi, S
Malabarba, L
Pietra, D
Passamonti, F
Bergamaschi, G
Lazzarino, M
Cazzola, M
BLOOD, 2004, 104 (11) : 649A - 650A
[22] IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?
Atilla, E.
Atilla, P. Ataca
Turedi, O.
Bozdag, S. Civriz
Toprak, S. Kocak
Akan, H.
Beksac, M.
Arslan, O.
Topcuoglu, P.
Ozcan, M.
Ilhan, O.
Ruhi, H. I.
Gurman, G.
Dalva, K.
HAEMATOLOGICA, 2016, 101 : 506 - 506
[23] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) of low and intermediate-1 risk. Results of the outpatient MDS registry
Schmitz, S.
Boettger, I
Schnell, R.
Lerchenmueller, C.
Sauer, A.
Severin, K.
Germing, U.
Steinmetz, H. T.
ONKOLOGIE, 2012, 35 : 148 - 148
[24] Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis
Li, Liunan
Jabbour, Elias
Borthakur, Gautam
Faderl, Stefan
Kadia, Tapan
Ravandi, Farhad
Pierce, Sherry A.
Wierda, William G.
Abruzzo, Lynne V.
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD, 2010, 116 (21) : 1212 - 1212
[25] EXPERIENCE WITH THE USE OF 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OF LOW/INTERMEDIATE RISK
Llorente Dunia, De Miguel
Lopez Nuria, Golbano
Morfa Miguel, Diaz
Juanis Jaime, Arbeteta
Sanz Dolores, Morales
Perez Dolores, Subira
Maqueda Cristina, Fernandez
Ramo Alejandro, Vazquez
Martin Sonia, Herrero
Albiz Blanca, Pinedo
HAEMATOLOGICA, 2016, 101 : 152 - 152
[26] Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
Lyons, Roger M.
Larson, Richard A.
Kosmo, Michael A.
Gandhi, Sunil
Liu, Delong
Chernoff, Marc
Dreisbach, Luke
Matei, Carmen
Hu, Kuolong
Franklin, Janet L.
Berger, Dietmar
BLOOD, 2009, 114 (22) : 703 - 704
[27] Cause of death in patients with lower-risk myelodysplastic syndrome (MDS)
Conley, A. P.
Stevenson, W.
Pierce, S.
Cortes, J. E.
O'Brien, S. M.
Ravandi, F.
Kantarjian, H. M.
Garcia-Manero, G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[28] Is IBD a Risk Factor for Myelodysplastic Syndrome (MDS)?
Lichtenstein, Gary
Blonski, Wojciech
Blaney, Kathleen
Marchioni, Renee
Buchner, Anna
Mudireddy, Prashant
Weiner, Mark
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S631 - S632
[29] EXPOSURE TO CHEMICALS AND RISK FOR MYELODYSPLASTIC SYNDROME (MDS)
SANDLER, DP
SHORE, DL
LIU, E
BLOOMFIELD, CD
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 141 (11) : S60 - S60
[30] STUDY OF THE IN VITRO EFFECT OF THE NONPEPTIDE THROMBOPOIETIN -RECEPTOR AGONIST SB-497115 (ELTROMBOPAG) ON MEGAKARYOPOIESIS OF PATIENTS WITH LOW/INTERMEDIATE-I RISK MYELODYSPLASTIC SYNDROME
Mavroudi, I.
Psyllaki, M.
Pyrovolaki, K.
Gvazava, G.
Kalpadakis, C.
Papadaki, H. A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 91 - 92

← 1 2 3 4 5 →